PF-3450074
CAS No. 1352879-65-2
PF-3450074( PF3450074 | PF-74 | PF74 )
Catalog No. M11434 CAS No. 1352879-65-2
PF-3450074 (PF74) is a small molecule HIV capsid protein, destabilized the viral capsid in vitro; acts at an early stage of HIV-1 infection and inhibits reverse transcription in target cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 39 | Get Quote |
|
10MG | 71 | Get Quote |
|
25MG | 120 | Get Quote |
|
50MG | 203 | Get Quote |
|
100MG | 357 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePF-3450074
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-3450074 (PF74) is a small molecule HIV capsid protein, destabilized the viral capsid in vitro; acts at an early stage of HIV-1 infection and inhibits reverse transcription in target cells.
-
DescriptionPF-3450074 (PF74) is a small molecule HIV capsid protein, destabilized the viral capsid in vitro; acts at an early stage of HIV-1 infection and inhibits reverse transcription in target cells, induced the rapid dissolution of the HIV-1 capsid; PF74 antiviral activity is promoted by binding of the host protein cyclophilin A to the HIV-1 capsid, and PF74 and cyclosporine exhibited mutual antagonism.
-
In VitroPF-3450074 (PF-74) exhibits anti-viral activities against HIV wild type NL4-3 andHIV T107N mutant with EC50 values of 0.72 μM and 4.5μM, respectively.PF-3450074 (PF-74) displays a good potency in primary human peripheral blood mononuclear cells (PBMCs), inhibits HIV-193RW025, HIV-1JR-CSF and HIV-193MW965 with IC50 values of 1.5 ± 0.9 μM; 0.6 ± 0.20 μM; and 0.6 ± 0.10 μM, respectively. This compound shows Median IC50?and CC50?values of 0.9 ± 0.5 μM and 90.5 ± 5.9 μM, respectively.The KD?for the interaction between?PF-74?and the CA hexamer, derived in the same manner as for NUP153, is determined to be 176 ± 78 nM.PF-3450074 (PF-74) (10 μM; 8 hours) results in a marked reduction in late products of reverse transcription in HeLa-P4 cells with DNase I-treated stocks of Env-defective HIV-1 (R9.Env-). RT-PCR Cell Line:HeLa-P4 cells Concentration:10 μMIncubation Time:8 hours Result:Inhibited HIV-1 reverse transcription in target cells.
-
In Vivo——
-
SynonymsPF3450074 | PF-74 | PF74
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1352879-65-2
-
Formula Weight425.532
-
Molecular FormulaC27H27N3O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (587.52 mM)
-
SMILESO=C(N[C@@H](CC1=CC=CC=C1)C(N(C)C2=CC=CC=C2)=O)CC3=C(C)NC4=C3C=CC=C4
-
Chemical Name2-Methyl-N-[(1S)-2-(methylphenylamino)-2-oxo-1-(phenylmethyl)ethyl]- 1H-indole-3-acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shi J, et al. J Virol. 2011 Jan;85(1):542-9.
2. Shi J, et al. J Virol. 2015 Jan;89(1):208-19.
3. Zhou J, et al. J Virol. 2015 Sep;89(17):9068-79.
4. Saito A, et al. J Virol. 2016 May 27;90(12):5808-5823.
molnova catalog
related products
-
N.41
N.41 (HIV inhibitor N.41, Vif inhibitor N.41) is a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G (A3G) protein (IC50=2.2 uM).
-
DPC-681
A potent and selective inhibitor of HIV-1 protease with IC90 of 4-40 nM.
-
DRB
DRB is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II (IC50 range of 4-10 μM).